Square Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was BDT135,934 Mil.
Warning Sign:
If a company builds assets at 10.6% a year, faster than its revenue growth rate of 9.6% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Square Pharmaceuticals's average Total Assets Growth Rate was 4.40% per year.
During the past 3 years, the average Total Assets Growth Rate was 13.40% per year.
During the past 5 years, the average Total Assets Growth Rate was 10.60% per year.
During the past 13 years, Square Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 17.70%. The lowest was 6.70%. And the median was 11.00%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Square Pharmaceuticals's Total Assets for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Square Pharmaceuticals (DHA:SQURPHARMA) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Square Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Square Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of Square Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Square Pharmaceuticals (DHA:SQURPHARMA) Business Description
Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceuticals products, Basic chemical products, and animal health products. It manufactures drugs like paracetamol, clotrimazole, antiallergic, Nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs. The company operates in Bangladesh and sells its products locally and internationally. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DHA:SQURPHARMA has been successfully added to your 